OBJECT: Stereotactic radiosurgery serves as an important primary and adjuvant treatment option for patients with many types of intracranial meningiomas. This is particularly true for patients with parasellar meningiomas. In this study, the authors evaluated the outcomes of Gamma Knife surgery (GKS) used to treat parasellar meningiomas. METHODS: The study is a retrospective review of the outcomes in 138 patients with meningiomas treated at the University of Virginia from 1989 to 2006; all patients had a minimum follow-up of 24 months. There were 31 men and 107 women whose mean age was 54 years (range 19-85 years). Eighty-four patients had previously undergone resection. The mean pre-GKS tumor volume was 7.5 ml (range 0.2-54.8 ml). Clinical and radiographic evaluations were performed, and factors related to favorable outcomes in each case were assessed. RESULTS: The mean follow-up duration was 84 months (median 75.5 months, range 24-216 months). In 118 patients (86%), the tumor volume was unchanged or had decreased at last follow-up. Kaplan-Meier analysis demonstrated radiographic progression-free survival at 5 and 10 years to be 95.4% and 69%, respectively. Fourteen patients (10%) developed new cranial nerve palsies following GKS. Factors associated with tumor control included younger age, a higher isodose, and smaller tumor volume. A longer follow-up duration was associated with either a decrease or increase in tumor volume. Fourteen patients (10%) experienced new or worsening cranial nerve deficits after treatment. Factors associated with this occurrence were larger pretreatment tumor volume, lower peripheral radiation dose, lower maximum dose, tumor progression, and longer follow-up. CONCLUSIONS: Gamma Knife surgery offers an acceptable rate of tumor control for parasellar meningiomas and accomplishes this with a low incidence of neurological deficits. Radiological control after radiosurgery is more likely in those patients with a smaller tumor volume and a higher prescription dose.
OBJECT: Stereotactic radiosurgery serves as an important primary and adjuvant treatment option for patients with many types of intracranial meningiomas. This is particularly true for patients with parasellar meningiomas. In this study, the authors evaluated the outcomes of Gamma Knife surgery (GKS) used to treat parasellar meningiomas. METHODS: The study is a retrospective review of the outcomes in 138 patients with meningiomas treated at the University of Virginia from 1989 to 2006; all patients had a minimum follow-up of 24 months. There were 31 men and 107 women whose mean age was 54 years (range 19-85 years). Eighty-four patients had previously undergone resection. The mean pre-GKS tumor volume was 7.5 ml (range 0.2-54.8 ml). Clinical and radiographic evaluations were performed, and factors related to favorable outcomes in each case were assessed. RESULTS: The mean follow-up duration was 84 months (median 75.5 months, range 24-216 months). In 118 patients (86%), the tumor volume was unchanged or had decreased at last follow-up. Kaplan-Meier analysis demonstrated radiographic progression-free survival at 5 and 10 years to be 95.4% and 69%, respectively. Fourteen patients (10%) developed new cranial nerve palsies following GKS. Factors associated with tumor control included younger age, a higher isodose, and smaller tumor volume. A longer follow-up duration was associated with either a decrease or increase in tumor volume. Fourteen patients (10%) experienced new or worsening cranial nerve deficits after treatment. Factors associated with this occurrence were larger pretreatment tumor volume, lower peripheral radiation dose, lower maximum dose, tumor progression, and longer follow-up. CONCLUSIONS: Gamma Knife surgery offers an acceptable rate of tumor control for parasellar meningiomas and accomplishes this with a low incidence of neurological deficits. Radiological control after radiosurgery is more likely in those patients with a smaller tumor volume and a higher prescription dose.
Authors: Kerstin A Kessel; Hanna Fischer; Markus Oechnser; Claus Zimmer; Bernhard Meyer; Stephanie E Combs Journal: Strahlenther Onkol Date: 2017-06-15 Impact factor: 3.621
Authors: Leland Rogers; Igor Barani; Marc Chamberlain; Thomas J Kaley; Michael McDermott; Jeffrey Raizer; David Schiff; Damien C Weber; Patrick Y Wen; Michael A Vogelbaum Journal: J Neurosurg Date: 2015-01 Impact factor: 5.115
Authors: I Jonathan Pomeraniec; Hideyuki Kano; Zhiyuan Xu; Brandon Nguyen; Zaid A Siddiqui; Danilo Silva; Mayur Sharma; Hesham Radwan; Jonathan A Cohen; Robert F Dallapiazza; Christian Iorio-Morin; Amparo Wolf; John A Jane; Inga S Grills; David Mathieu; Douglas Kondziolka; Cheng-Chia Lee; Chih-Chun Wu; Christopher P Cifarelli; Tomas Chytka; Gene H Barnett; L Dade Lunsford; Jason P Sheehan Journal: J Neurosurg Date: 2017-10-27 Impact factor: 5.115
Authors: Andrew Faramand; Hideyuki Kano; Ajay Niranjan; Stephen A Johnson; Mohab Hassib; Kyung-Jae Park; Yoshio Arai; John C Flickinger; L Dade Lunsford Journal: J Neurooncol Date: 2018-04-24 Impact factor: 4.130
Authors: Henry Ruiz-Garcia; Daniel M Trifiletti; Nasser Mohammed; Yi-Chieh Hung; Zhiyuan Xu; Tomas Chytka; Roman Liscak; Manjul Tripathi; David Arsanious; Christopher P Cifarelli; Marco Perez Caceres; David Mathieu; Herwin Speckter; Gregory P Lekovic; Gautam U Mehta; Jason P Sheehan Journal: World Neurosurg Date: 2020-11-03 Impact factor: 2.104